Open Journal Systems

Investigating the health-economic profiles of biomarker-driven immunosuppresion (BIO-DrIM) following solid organ transplantation

Simon A Weber, Malte Pietzsch, Oriol Bestard, Josep M Grinyo, Ondrej Viklicky, Petra Reinke

Abstract

Immunosuppression (IS) following solid organ transplantation is indicated to avoid rejection but puts a sig-nificant burden on patients and healthcare systems due to life-long medication dependency and associated costs. Or-gan-tolerance with low or no IS medication has been observed, and might be forecasted with the help of appropriate biomarkers. Individualized treatments raise the question whether benefits of individualization outweigh the costs of stratification. This article outlines the importance of early economic evaluation in the context of biomarker-guided IS and discusses challenges that an economic evaluation should address, using the BIO-DrIM project as a reference exam-ple. We report on design aspects and health-economic study integration into several newly designed biomarker trials. In these studies, health-economic endpoints were defined to measure benefits of individualization and to compare them to the costs associated with stratification. Key economic outcomes to be collected are resource consumption and patient quality of life. Test accuracy of the biomarker-stratification is critical for the clinical success and the health-economic viability of an individualized reduced IS regime. However, IS regimes are not well standardized, rendering comparator choice difficult. The multi-national character of the trials adds further complexity that needs to be addressed. Develop-ers of biomarker tests should stress the importance of integrating health-economic evaluations early into prod-uct-development.

Keywords

transplantation; immunosuppression; biomarker; individualized medicine; cost-effectiveness; cost-utility; micro-costing

Full Text:

PDF

References

Abboudi H and MacPhee I A M, 2012, Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. Pharmacogenomics and Personalized Medicine, vol.5: 63–72.

Olbricht C J, 2012, Why do we need biomarkers in solid organ transplantation. Clinica Chimica Acta, 1310–1311.

Baron D, Giral M and Brouard S, 2015, Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes. Transplant International, vol.28: 938–959.

Woodroffe R, Yao G L, Meads C, et al. 2005, Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technology Assessment, vol.9(21).

Haller M and Oberbauer R, 2008, Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. Transplant International, vol.22: 69–77.

Hernadez-Fuentes M P and Lechler R I, 2010, A ‘bio-marker signature’ for tolerance in transplantation. Nature Reviews Nephrology, vol.6: 606–613.

Lerut J and Sanchez-Fueyo A, 2006, An appraisal of tolerance in liver transplantation. American Journal of Transplantation, vol.6: 1774–1780.

Babel N, Reinke P and Volk H-D, 2009, Lymphocyte markers and prediction of long-term renal allograft acceptance. Current Opinion in Nephrology and Hyper-tension, vol.18: 489–494.

Bestard O, Cruzado J M, Ia Franquesa M, et al. 2010, Biomarkers in renal transplantation. Current Opinion in Organ Transplantation, vol.15: 467–473.

Goodacre S and Thokala P, 2015, The economics of cardiac biomarker testing in suspected myocardial infarction. Clinical Biochemistry, vol.48: 213–217.

Bestard O, Cruzado J M, Lucia M, et al. 2013, Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney International, vol.84: 1226–1236.

McEwan P, Dixon S, Baboolal K, et al. 2006, Evaluation of the cost-effectiveness of sirolimus versus tac-rolimus for immunosuppression following renal trans-plantation in the UK. Pharmacoeconomics, vol.24(1): 67–79.

Jürgensen J S, Arns W and Hass B, 2010, Cost-effectiveness of immunosuppressive regimens in renal trans-plant recipients in Germany: a model approach. European Journal of Health Economics, vol.11: 15–25.

Muduma G, Shaw J, Hart W M, et al. 2014, Cost utility analysis of immunosuppressive regimens in adult renal transplant recipients in England and Wales. Patient Preference and Adherence, vol.8: 1537–1546.

Hall P S and McGabe C, 2013, What evidence is there for the reimbursement of personalised medicine? Pharmacoeconomics, vol.31: 181–183.

Ijzerman M J and Steuten L M G, 2011, Early assessment of medical technologies to inform product development and market access — a review of methods and applications. Applied Health Economics & Health Pol-icy, vol. 9(5): 331–347.

Backhouse M E, Wonder M, Hornby A, et al. 2011, Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value in Health, vol.14: 608–615.

Drummond M, Tarricone R and Torbica A, 2013, Assessing the added value of health technologies: recon-ciling different perspectives. Value in Health, vol.16: S7–S13.

Sculpher M and Claxton K, 2010, Sins of omission and obfuscation: IQWiG`s guidelines on economic evaluation. Health Economics, vol.19: 1132–1136.

Cohen D J and Rexnolds M R, 2008, Interpreting the results of cost-effectiveness studies. Journal of the American College of Cardiology, vol.52(25): 2119–2126.

Chuang L-H and Whitehead S J, 2011, Mapping for economic evaluation. British Medical Bulletin, vol.101: 1–15.

Laupacis A, Pus N, Muirhead N, et al. 1993, Dis-ease-specific questionnaire for patients with a renal transplant. Nephron, vol.64: 226–231.

Rebollo P, Ortega F, Ortega T, et al. 2003, Spanish validation of the “Kidney Transplant Questionnaire”: a useful instrument for assessing health-related quality of life in kidney transplant patients. Health and Quality of Life Outcomes, vol.1: 56.

Rostami Z, Tavallaii S A, Jahani Y, et al. 2011, Assessment of quality of life in a single-center transplantation population using the Kidney Transplant Questionnaire-25 questionnaire. Transplantation Proceedings, vol.43: 590–591.

Chisholm-Burns M A, Erickson S R, Spivey C A et al. 2011, Concurrent validity of kidney transplant questionnaire in US renal transplant recipients. Patient Preference and Adherence, vol.5: 517–522.

Ramsey S, Willke R, Glick H, et al. 2015, Cost-effectiveness analysis alongside clinical trials II — an ISPOR good research practices task force report. Value in Health, vol.18: 161–172.

Husereau D, Drummond M, Petrou S, et al. 2013, Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine, vol.11: 80.

Petrou S and Gray A, 2011, Economic evaluation along-side randomized controlled trials: design, conduct, analysis, and reporting. British Medical Journal, vol.342: d1548.

Fiebiger W, Mitterbauer C and Oberbauer R, 2004, Health-related quality of life outcomes after kidney trans-plantation. Health and Quality of Life Outcomes, vol.2: 2.

Xu X, Nardini H K G and Ruger J P, 2014, Micro-costing studies in the health and medical literature: protocol for a systematic review. Systematic Reviews, vol.3(47).

Abou-El-Enein M, Römhild A, Kaiser D, et al. 2013, Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy, vol.15: 362–383.

Fitzgerald P, Goodacre S W, Cross E, et al. 2011, Cost- effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the Randomized Assessment of Treatment Using Panel Assay of Cardiac markers (RATPAC) trial. Society for Academic Emergency Medicine, vol.18(5): 488–495.

O`Sullivan A K, Thompson D and Drummond M, 2005, Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value in Health, vol.8(1): 67–79.

Dziura J D, Post L A, Zhao Q, et al. 2013, Strategies for dealing with missing data in clinical trials: from design to analysis. Yale Journal of Biology and Medicine, vol.86: 343–358.

Miners A, 2008, Estimating costs for cost-effectiveness analysis. Pharmacoeconomics, vol.26(9): 745–751.

Institute for Quality and Efficiency in Health Care (IQWiG), 2009, Working paper — cost estimation, ver-sion 1.0, accessed March 5, 2015,

Shi L, Hodges M, Drummond M, et al. 2010, Good re-search practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the IS-POR drug cost task force report — part VI. Value in Health, vol.13: 28–33.

The University of York — Centre for Health Economics, 2015, NICE Threshold Press release, accessed February 21, 2015,

Kasiske B L, Zeier G M, Chapman J R, et al. 2010, KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, vol.77: 299–311.

Baker R, Jardine A and Andrews P, 2011, Post-operative care of the kidney transplant recipient, 5th edition Final Version, The Renal Association, accessed February 5, 2011,

Rivero-Arias O and Gray A, 2010, The multinational nature of cost-effectiveness analyses alongside multina-tional clinical trials. Value in Health, vol.13(1): 34–41.


DOI: http://dx.doi.org/10.18063/APM.2016.01.004
(316 Abstract Views, 188 PDF Downloads)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Simon A Weber, Malte Pietzsch, Oriol Bestard, Josep M Grinyo, Ondrej Viklicky, Petra Reinke

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

                                          

Advances in Precision Medicine is a peer-reviewed, open-access journal. All journal content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.